Yahoo Web Search

Search results

      • Each INN is a unique name that is globally recognized and is public property. A nonproprietary name is also known as a generic name.
      extranet.who.int › tools › inn_global_data_hub
  1. People also ask

  2. assign nonproprietary names to medicinal substances, so that each substance would be recognized globally by a unique name. These INNs do not give proprietary rights, unlike a trade mark, and can be used freely as they are public property. INNs have been assigned to biological products since the early days of the INN Programme.

  3. This document, first published on the website of the INN Programme in 2006, presents an inventory of the policy decisions taken by the INN Expert Group during these years of change, and of the names assigned to biological and biotechnological substances.

  4. Dec 11, 2023 · International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2022. 11 December 2023. | Publication. Download (1.2 MB)

  5. The School of INN (International Nonproprietary Names) In 1950 WHO established the INN Programme to provide a common language for people all over the world to work together for the safe and effective use of medicines. The main objective of the programme is to. define a single, unique, globally accepted name for each pharmaceutical substance.

  6. International Nonproprietary Names (INN) facilitate the identification of pharmaceutical substances or active pharmaceutical ingredients. Each INN is a unique name that is globally recognized and is public property. A nonproprietary name is also known as a generic name. General guidance.

  7. nonproprietary names are selected for these inactive moieties, and published in proposed lists under the title "names for radicals and groups". If a "radical and group name" is used in conjunction with an INN, it is also referred to as an INNM. In some cases, a name of an INN Radical describes more than one substituent, e.g. (names in

  8. Feb 21, 2019 · International Nonproprietary Names (INN) are assigned to active pharmaceutical substances by the World Health Organization (WHO) following the World Health Assembly Resolution WHA3.11 approved in 1953. The INN Programme for pharmaceutical substances was estab-lished in 1953 and the INN Expert Group was officially designated to